Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

Background: Aprepitant is a highly selective substance P (neurokinin 1 [NK1] receptor) antagonist that significantly improves the pharmacotherapy of acute and delayed highly emetogenic chemotherapy-induced nausea and vomiting, probably through an action in the brain stem region of the central nervous system. Here, we report the use of positron emission tomography imaging with the NK1 receptor binding selective tracer [F-18]SPA-RQC to determine the levels of central NK1 receptor occupancy achieved by therapeutically relevant doses of aprepitant in healthy humans. Methods: Two single-blind, randomized, placebo-controlled studies in healthy subjects were performed. The first study evaluated the plasma concentration-occupancy relationships for aprepitant dosed orally at 10, 30, 100, or 300 mg, or placebo (n = 12). The second study similarly evaluated oral aprepitant 30 mg and placebo (n = 4). in each study, dosing was once daily for 14 consecutive days. Data from both studies were combined for analyses. The ratio of striatal/cerebellar [F-18]SPA-RQ (high receptor density region/reference region lacking receptors) was used to calculate trough receptor occupancy 24 hours after the last dose of aprepitant. Results: Brain NK1 receptor occupancy increased after oral aprepitant dosing in both a plasma concentration-related (r = .97; 95016 confidence interval [CI] = .94-1.00, p < .001) and a dose-related (r = .94; 95% CI = .86-1.00, p < .001) fashion. High ( greater than or equal to90%) receptor occupancy was achieved at doses of 100 mg/day or greater. The plasma concentrations of aprepitant that achieved 50% and 90% occupancy were estimated as approximately 10 ng/mL and approximately 100 ng/mL, respectively. Conclusions: Positron emission tomography imaging with [F-18]SPA-RQ allows brain NK1 receptor occupancy by aprepitant to be predicted from plasma drug concentrations and can be used to guide dose selection for clinical trials of NK1 receptor antagonists in central therapeutic indications.